Replies to post #432500 on NorthWest Biotherapeutics Inc (NWBO)

[TheFollower]

Thanks, John. Nice find.

[flipper44]

Thanks John! I further highlighted a passage you selected from the article.

With the benefit of a shared quality system, faster internal technical transfer, and process crossover between teams helping to reduce program bottlenecks and providing a seamless experience, we are now uniquely positioned to help our clients accelerate and achieve critical development goals from discovery to commercialization.

https://www.criver.com/insights/charles-river-integrates-cell-and-gene-therapy-acquisitions-enhance-end-end-offering-developers

Now go back to recent Dave Innes comments to Kabunushi.

It’s a multifaceted answer with tons of possibilities.
I believe that there is an advantage for cognate/crl due to the fact the have already been qualified under the tougher European standards to make vaccine for the US trial and compassionate use. The question/answer can be multi faceted because of Flaskworks.
If we get the facility certified for Flaskworks by MHRA, does that change the calculus for how CRL proceeds. Obviously are many possibilities.
We have worked with CRL before on other projects and like the way they operate. They are a terrific company that potentially could offer all hands on deck approach once is decided which direction they are headed.
As an example/possibility, would they use current technology to ramp production while they duplicate what we have done at Sawston with Flaskworks. This is of course if they are interested in FW and working with us.
As the options unfold,I hope we will be able to add a lot more color

[eagle8]

Thanks for sharing john1045.
Good find.

GLTU

[Doc logic]

john1045,

Definitely a nice piece of the puzzle to be put into place. Thanks and best wishes.